Yoshito Ohnuma
Sapporo Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yoshito Ohnuma.
Journal of the American College of Cardiology | 2001
Tetsuji Miura; Yongge Liu; Mahiko Goto; Akihito Tsuchida; Takayuki Miki; Atsushi Nakano; Yasuhiro Nishino; Yoshito Ohnuma; Kazuaki Shimamoto
OBJECTIVES The possible role of the ATP-sensitive potassium (KATP) channel in cardioprotection by Na+-H+ exchange (NHE) inhibition was examined. BACKGROUND The KATP channel is suggested to be involved not only in ischemic preconditioning but also in some pharmacological cardioprotection. METHODS Infarction was induced by 30-min coronary occlusion in rabbit hearts in situ or by 30-min global ischemia in isolated hearts. Myocardial stunning was induced by five episodes of 5-min ischemia/5-min reperfusion in situ. In these models, the effects of NHE inhibitors (cariporide and ethylisopropyl-amiloride [EIPA]) and the changes caused by KATP channel blockers were assessed. In another series of experiments, the effects of EIPA on mitochondrial KATP (mito-KATP) and sarcolemmal KATP (sarc-KATP) channels were examined in isolated cardiomyocvtes. RESULTS Cariporide (0.6 mg/kg) reduced infarct size in situ by 40%, and this effect was abolished by glibenclamide (0.3 mg/kg), a nonselective KATP channel blocker. In vitro, 1 microM cariporide limited infarct size by 90%, and this effect was blocked by 5-hydroxydecanoate (5-HD), a mito-KATP channel blocker but not by HMR1098, a sarc-KATP channel blocker. Infarct size limitation by 1 microM EIPA was also prevented by 5-HD. Cariporide attenuated regional contractile dysfunction by stunning, and this protection was abolished by glibenclamide and 5-HD. Ethylisopropyl amiloride neither activated the mito-KATP channel nor enhanced activation of this channel by diazoxide, a KATP channel opener. CONCLUSIONS Opening of the mito-KATP channel contributes to cardioprotection by NHE inhibition, though the interaction between NHE and this KATP channel remains unclear.
Journal of the American College of Cardiology | 2002
Akihito Tsuchida; Tetsuji Miura; Masaya Tanno; Jun Sakamoto; Takayuki Miki; Atsushi Kuno; Tomoaki Matsumoto; Yoshito Ohnuma; Yoshihiko Ichikawa; Kazuaki Shimamoto
OBJECTIVES This study aimed to examine:1) whether nicorandil protects the ischemic myocardium by activating sarcolemmal adenosine triphosphate (ATP)-sensitive K(+) (sarcK(ATP)) channels or the mitochondrial K(ATP) (mitoK(ATP)) channels, and 2) whether protein kinase C (PKC) activity is necessary for cardioprotection afforded by nicorandil. BACKGROUND Nicorandil is a hybrid of nitrate and a K(ATP) channel opener that activates the sarcK(ATP) and mitoK(ATP) channels. Both of these K(ATP) channels are regulated by PKC, and this kinase may be activated by nitric oxide and also by oxygen free radicals (OFR) generated after mitoK(ATP) channel opening. METHODS In isolated rabbit hearts, infarction was induced by 30-min global ischemia/2-h reperfusion with monitoring of the activation recovery interval (ARI), an index of action potential duration. Protein kinase C translocation was assessed by Western blotting. RESULTS Nicorandil did not change ARI before ischemia, but it accelerated ARI shortening after the onset of ischemia and reduced infarct size by 90%. A sarcK(ATP) channel selective blocker, HMR1098, abolished acceleration of ischemia-induced ARI-shortening by nicorandil and eliminated 40% of nicorandil-induced infarct size limitation. A mitoK(ATP) channel selective blocker, 5-hydroxydecanoate, abolished the protection afforded by nicorandil without affecting ARI. Cardioprotection by nicorandil was inhibited neither by an OFR scavenger, N-2-mercaptopropionylglycine nor by a PKC inhibitor, calphostin C, at a dose that was capable of inhibiting PKC- epsilon translocation after preconditioning. CONCLUSIONS Both the sarcK(ATP) and mitoK(ATP) channels are involved in anti-infarct tolerance afforded by nicorandil, but PKC activation induced by nitric oxide or OFR generation, if any, does not play a crucial role.
Basic Research in Cardiology | 2003
Yukinaga Nozawa; Tetsuji Miura; Takayuki Miki; Yoshito Ohnuma; Toshiyuki Yano; Kazuaki Shimamoto
Abstract To obtain insight into the role of the mitochondrial ATP-sensitive K+ (mitoKATP) channel in ischemic preconditioning (PC), we aimed to clarify the mitoKATP channel-dependent phase of PC in two PC protocols with different intervals between PC ischemia and an index ischemia. The possible contribution of mitoKATP channel opening to protein kinase C activation in PC was also examined by Western blotting. Myocardial infarction was induced by 30-min coronary occlusion/2-h reperfusion in rat hearts in situ, and infarct size was expressed as a percentage of the area at risk (% IS/AR). PC was performed with 2 episodes of 5-min ischemia, and each heart was subjected to 30-min ischemia either 5 min or 20 min after PC. At 5 min after PC, both PKC-δ and -ε were translocated and the myocardium was protected against infarction (% IS/AR = 28.3 ± 2.7 % vs. 72.7 ± 2.2 in controls p < 0.05). Pretreatment with a selective mitoKATP channel blocker, 5-hydroxydecanoate (5-HD, 10 mg/kg), abolished the cardioprotection but not PKC translocation by PC. At 20 min after PC, PKC translocation remained at the same level as that 5 min after PC, but the anti-infarct tolerance was attenuated (%IS/AR = 43.5 ± 4.7 %). Injection of 5-HD after PC did not affect anti-infarct tolerance at 5 min after PC but abolished the protection at 20 min after PC without any effects on PKC. These results suggest that the mitoKATP channel plays a role in triggering of PC in a PKC-independent manner and that the role of the mitoKATP channel as a mediator of protection is detectable after, but not before, the PC effect starts to decay without a change in the level of PKC translocation in the rat heart.
Internal Medicine | 2016
Junichi Nishida; Nobuaki Kokubu; Mina Kawamukai; Akiyoshi Hashimoto; Hirofumi Ohnishi; Hidemichi Kouzu; Yoshito Ohnuma; Tohru Hasegawa; Akihito Tsuchida; Tetsuji Miura
OBJECTIVE Chronic kidney disease is a risk factor of coronary events, however, its impact on coronary artery stenosis has not yet been clarified with the use of a large database. We examined the association between a reduced glomerular filtration rate (GFR) and the overall severity of coronary stenosis. METHODS We enrolled 1,150 patients [mean age, 68±12 (SD) years; 66.6% men] who consecutively underwent coronary angiography for suspected stable angina pectoris. The overall severity of stenosis in the coronary arteries was assessed by the Gensini score (GS), and its logarithmic values (log-GS) were used for statistical analyses since the GS does not follow a normal distribution. RESULTS The log-GS was significantly larger in men than in women (2.5±1.5 vs. 1.9±1.7), while the estimated GFR (eGFR) and comorbidities were comparable between both sexes. A multivariate regression analysis indicated that age, smoking, eGFR, HDL-cholesterol and HbA1c were independent explanatory variables of the log-GS in men, although the eGFR explained only 1.2% of the log-GS variation. In women, the eGFR was not included in the significant explanatory variables shown by the multivariate analysis. However, the sex difference in the regression for the eGFR-log-GS relationship was not statistically significant. CONCLUSION A reduced eGFR is a significant, but minor, determinant of the overall severity of coronary artery stenosis in men and potentially women.
American Journal of Physiology-heart and Circulatory Physiology | 2002
Yoshito Ohnuma; Tetsuji Miura; Takayuki Miki; Masaya Tanno; Atsushi Kuno; Akihito Tsuchida; Kazuaki Shimamoto
American Journal of Physiology-heart and Circulatory Physiology | 2004
Tetsuji Miura; Yoshito Ohnuma; Atsushi Kuno; Masaya Tanno; Yoshihiko Ichikawa; Yuichi Nakamura; Toshiyuki Yano; Takayuki Miki; Jun Sakamoto; Kazuaki Shimamoto
Naunyn-schmiedebergs Archives of Pharmacology | 2001
Masaya Tanno; Tetsuji Miura; Akihito Tsuchida; Takayuki Miki; Yasuhiro Nishino; Yoshito Ohnuma; Kazuaki Shimamoto
Journal of Hypertension | 2018
Tomohisa Yamashita; Sayaka Shimizu; Masayuki Koyama; Kouhei Ohno; Tomohiro Mita; Toshiyuki Tobisawa; Akifumi Takada; Nobuhiko Togashi; Yoshito Ohnuma; Tohru Hasegawa; Akihito Tsuchida; Toshiaki Endo; Toshiaki Ando; Hideaki Yoshida; Shingo Fukuma; Shunichi Fukuhara; Norihito Moniwa; Tetsuji Miura
Japanese Circulation Journal-english Edition | 2003
Yoshito Ohnuma; Tetsuji Miura; Takayuki Miki; Atsushi Nakano; Yoshihiko Ichikawa; Kazuaki Shimamoto
Japanese Circulation Journal-english Edition | 2003
Yoshihiko Ichikawa; Tetsuji Miura; Atsushi Nakano; Takayuki Miki; Jun Sakamoto; Yoshito Ohnuma; Kazuaki Shimamoto
Collaboration
Dive into the Yoshito Ohnuma's collaboration.
National Institute of Advanced Industrial Science and Technology
View shared research outputs